Natrecor to Be Reviewed by Cardiovascular and Renal Drugs Advisory Committee
SUNNYVALE, Calif., May 25 /PRNewswire/ -- Scios Inc. (Nasdaq: SCIO)
announced that Nasdaq has halted trading of Scios common stock today, Friday,
May 25, 2001. The trading halt is due to the review of the Natrecor(R)
(nesiritide) New Drug Application by the Cardiovascular and Renal Drugs
Advisory Committee to the U.S. Food and Drug Administration (FDA). Natrecor
is currently under FDA review for the treatment of acute congestive heart
failure. The FDA is expected to complete its review of the Natrecor
application by July of 2001.
Following today's Advisory Committee review, Scios will host a conference
call and webcast to discuss the results of the meeting. The conference call
and webcast will begin at 6:00 p.m. (EDT). The webcast will be available on
Scios' Web site at http://www.sciosinc.com. The conference call dial-in will be
800-314-7867. A replay of both the conference call and webcast will be
available through June 1, 2001. The replay dial-in number will be
888-203-1112, confirmation code 593777.
Scios Inc.
Scios is a biopharmaceutical company developing novel treatments for heart
failure and rheumatoid arthritis. The company's disease-based technology
platform integrates expertise in protein biology with computational and
medicinal chemistry to identify novel targets and rationally design
small-molecule compounds to treat cardiovascular and inflammatory diseases,
two of the world's leading unmet medical needs. Additional information on
Scios is available on its Web site located at http://www.sciosinc.com and in the
company's various filings with the Securities and Exchange Commission (SEC).
The statements in this press release that are not historical facts are
forward-looking statements that involve risks and uncertainties. These
include uncertainties associated with anticipating the response of the FDA and
the Advisory Committee to the results of the VMAC trial, the timing of
regulatory approval of Natrecor, as well as other risks detailed from time to
time in the reports filed by Scios with the SEC, including the company's
annual report on form 10-K for the year ended December 31, 2000, and
subsequent reports filed on form 10-Q for the quarter ended March 31, 2001.
SOURCE Scios Inc.
 back to top
Related links:
http://www.sciosinc.com
CONTACT:
David Gryska of Scios Inc., 408-616-8328; or
Ed Bisno, 212-704-8212, or Thomas Lutazi, 212-704-8188, both of
Edelman Financial Worldwide, for Scios Inc.
|
